TICKERNERD
Menu
DRUGDRUGHealthcare · Biotechnology

DRUG Stock Forecast: Bright Minds Biosciences, Inc. Price Predictions for 2026-2027

Last close, 31 July 2026
$73

The 7 Wall Street analysts covering Bright Minds Biosciences, Inc. hold a median 12-month price target of $144 — +96.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 38 of 100 as at 1 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$718.8M
Ticker Nerd rank
38 / 100
Median analyst target
$144
Analysts covering
7
Ticker Nerd rank

DRUG stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Bright Minds Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
38 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
78
Value
71
Momentum
69
Size
49
Revisions
42
Issuance
33
Accruals
31
Growth
24
Volatility
20

Quality (78): The business earns solid, repeatable profits on what it owns.

Volatility (20): The share price moves around a lot.

The rank is the raw material. Whether the rules would actually own Bright Minds Biosciences, Inc. — and when they’d sell — is the membership.

Wall Street

DRUG stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on DRUG, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says7 analysts
7 Buy0 Hold0 Sell
Low $143Median $144High $216

The green dot is the last close — the median target sits +96.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
1 June 2026HC Wainwright & Co.ReiteratesBuy$145
20 May 2026Piper SandlerMaintainsOverweight—
13 Apr 2026JefferiesInitiatesBuy—
30 Mar 2026BTIGReiteratesBuy—
4 Mar 2026HC Wainwright & Co.MaintainsBuy—
17 Feb 2026BTIGMaintainsBuy—
7 Jan 2026BTIGMaintainsBuy—
6 Jan 2026BTIGMaintainsBuy—
2 Jan 2026Chardan CapitalMaintainsBuy—
30 Dec 2025HC Wainwright & Co.ReiteratesBuy—
15 Sept 2025HC Wainwright & Co.ReiteratesBuy—
8 Sept 2025BTIGInitiatesBuy—
19 Aug 2025HC Wainwright & Co.ReiteratesBuy—
2 July 2025Cantor FitzgeraldAssumesOverweight—
21 May 2025Chardan CapitalMaintainsBuy—
13 May 2025TD CowenInitiatesBuy—
7 May 2025Chardan CapitalInitiatesBuy—
19 Feb 2025HC Wainwright & Co.ReiteratesBuy—
23 Jan 2025Piper SandlerInitiatesOverweight—
10 Jan 2025Cantor FitzgeraldInitiatesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

DRUG analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
2
Fundamentals

Bright Minds Biosciences, Inc. (DRUG) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.3×

Cheaper than 72% of US stocks

Price / sales
—
Price / book
3.3×

Cheaper than 31% of US stocks

EV / EBITDA
−20.8×

Cheaper than 89% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 35% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−15.0%

Higher than 33% of US stocks

Return on assets
−10.4%

Higher than 26% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

DRUG vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
DRUGBright Minds Biosciences, Inc.$718.8M
38
XOMAXOMA Royalty Corp.$705.1M
—
FTHFaeth Therapeutics, Inc.$702.2M
56
MNPRMonopar Therapeutics, Inc.$724.1M
65
AURAAura Biosciences, Inc.$724.7M
64
ACRSAclaris Therapeutics, Inc.$726.3M
59
CADLCandel Therapeutics, Inc.$733.2M
58
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DRUG appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest DRUG news & analysis

Vistagen Appoints Douglas J. Williamson to its Board of Directors

GlobeNewsWire · 31 July 2026neutral

Vistagen announced the appointment of Douglas J. Williamson to its Board of Directors. Williamson joins the board of the late clinical-stage biopharmaceutical company focused on intranasal neuroscience product candidates called pherines.

Why it matters — While this news concerns Vistagen, not Bright Minds Biosciences, a DRUG watcher may note board appointments at peer neuroscience companies as signals of industry direction or governance trends in the space.

FAQ

Frequently asked questions about DRUG stock

What is the DRUG stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Bright Minds Biosciences, Inc. have a median 12-month price target of $144, with estimates ranging from $143 to $216. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is DRUG stock a buy right now?

Of the 7 analysts covering Bright Minds Biosciences, Inc., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Bright Minds Biosciences, Inc. 38 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank DRUG?

As at 1 Aug 2026, Bright Minds Biosciences, Inc. ranks 38 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (78 of 100).

Will DRUG stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +96.3% from the last close, and Ticker Nerd's factor model ranks Bright Minds Biosciences, Inc. 38 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the DRUG stock forecast for 2030?

No analyst covering Bright Minds Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DRUG are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $143 to $216 over the next 12 months.

What does Bright Minds Biosciences, Inc. do?

Bright Minds Biosciences Inc. is a biotechnology company specializing in the development of next-generation therapeutics for neuropsychiatric disorders.

What is the latest news on DRUG?

The most recent item we track (GlobeNewsWire, 31 July 2026): "Vistagen Appoints Douglas J. Williamson to its Board of Directors". Vistagen announced the appointment of Douglas J. Williamson to its Board of Directors. Williamson joins the board of the late clinical-stage biopharmaceutical company focused on intranasal neuroscience product candidates called pherines.

Company

About Bright Minds Biosciences, Inc.

Bright Minds Biosciences Inc. is a biotechnology company specializing in the development of next-generation therapeutics for neuropsychiatric disorders. The primary focus of the company is to design serotonergic compounds that have the potential to benefit patients struggling with mental health challenges. These compounds aim to modulate specific serotonin receptor subtypes, seeking to maximize therapeutic effects while minimizing adverse side effects. Bright Minds Biosciences is part of the broader pharmaceuticals and biotechnology industry, impacting sectors related to mental healthcare and treatment innovation. The company leverages advanced scientific knowledge and cutting-edge research methodologies to support advancements in the treatment of conditions such as depression, PTSD, and other mood disorders. With a mission centered on improving mental health care options, Bright Minds Biosciences plays an integral role in developing innovative solutions that address unmet medical needs in the neurology and psychiatry fields. Its work is paving the way for new therapies that could revolutionize patient care and expand the current pharmacopeia, providing hope and options for millions worldwide.

CEO Mr. Ian McDonald · 26 employees · United States · https://brightmindsbio.com